CDX-011: Selective Killing Of Breast Cancer Cells By Targeting Glycoprotein NMB

CDX-011 is an antibody attached to a cancer killing drug. The antibody delivers the drug to cancer cells by attaching to a protein called glycoprotein NMB (GPNMB) that is expressed on the surface of breast cancer cells. I like this approach because the treatment only targets cancer cells and not the normal cells (that don’t express GPNMB), thereby increasing its efficiency and reducing side effects. The following is a link to a breast cancer clinical trial using CDX-011.
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-Expressing Breast Cancer.

 
NEW! GENE TARGETED NUTRACEUTICAL DIET FOR ESTROGEN POSITIVE BREAST CANCERS NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*